Aarti Pharmalabs Ltd

Aarti Pharmalabs Employee Stock Options

Aarti Pharmalabs allotted 22,062 equity shares under its PSOP 2023 plan. This follows the exercise of stock options by eligible employees.

Aarti Pharmalabs Earnings Call: Key Takeaways

Aarti Pharmalabs reported Q4 FY26 revenue of ₹580 Cr (+9% YoY) but PAT declined to ₹62 Cr from ₹89 Cr due to higher costs and forex losses.

Aarti Pharmalabs Earnings Call: Key Takeaways

Aarti Pharmalabs reported FY26 standalone revenue of INR 17,976 Mn with a 23% EBITDA margin. Strategy focuses on CDMO expansion and backward integration for Xanthine derivatives.

Aarti Pharmalabs Management Change

Aarti Pharmalabs re-appointed its cost and internal auditors for 12 months. Additionally, Rajendra Pagare and Sachin Patil were designated as Senior Management Personnel.

Execution

12 months for auditors

Aarti Pharmalabs Dividend

Aarti Pharmalabs Limited recommended a final dividend of ₹0.4 per equity share for the financial year. The record date will be announced in due course.

Aarti Pharmalabs Employee Stock Options

Aarti Pharmalabs granted 57,600 stock options to employees at Rs. 5 each. This move under PSOP 2023 aims to align employee interests with shareholders.

Value

₹0.03 Cr

Aarti Pharmalabs Q4 FY26 Results: Net Profit ₹61.1 Cr, Down 30.8% YoY

Aarti Pharmalabs Ltd reported revenue from operations of ₹582.6 Cr (+3.3% YoY) and net profit of ₹61.1 Cr (-30.8% YoY) for Q4 FY26.

Key figure

Net profit ₹61.1 Cr · -30.8% YoY

Aarti Pharmalabs Financial Results

Aarti Pharmalabs reported its FY26 audited financial results and recommended a final dividend of Rs. 2 per share. The board also re-appointed cost and internal auditors.

Value

₹2.00 Cr

Aarti Pharmalabs Board Meeting Date

Aarti Pharmalabs postponed its May 18 board meeting to May 25, 2026. The trading window remains closed until May 27 following financial results declaration.